Rifaximin for Pertuzumab-Related GI Toxicities

Frontiers in Oncology

Alvaro Moreno-Aspitia¹  Gina Reynolds¹  Aixa E. Soyano¹  Saranya Chumsri¹ 

[1] Robert and Monica Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, United States;

关键词: HER2 positive breast cancer;    rifaximin;    pertuzumab;    trastuzumab;    diarrhea;    gastrointestinal toxicities;   

DOI  :  10.3389/fonc.2017.00168

来源: DOAJ

【 摘 要 】

Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.

【 授权许可】

Unknown